15 Drugs Approved for Primary Care in 2022

FDA Approves Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections

Slideshow

With 2022 at an end, Patient Care Online has compiled a list of key drugs approved by the US Food and Drug Administration (FDA) for conditions that are often seen in primary care. Scroll through the slides below to find details on a new oral solution of amlodipine; the first and only FDA-approved, once-daily amphetamine transdermal patch for the treatment of attention deficit hyperactivity disorder; the first and only specific interleukin-23 inhibitor to be approved for the treatment of Crohn disease in adults; the first drug indicated for the treatment for eosinophilic esophagitis; a novel rapid-acting treatment for major depressive disorder; and 10 more.

Related Content

Patient Care Editorial Staff

October 25th 2024

FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions

Oral sulopenem is the first oral penem approved in the US for treating uUTIs in women with limited options.

FDA Updates Flublok Label with Safety Data for Pregnant Individuals

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

FDA Grants Priority Review to GSK NDA for First-In-Class Oral Antibiotic

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

October 16th 2024

FDA Approves Next-Gen Noninvasive CRC Screening Test: Daily Dose

The FDA today accepted GSK's NDA for gepotidacin for the treatment of uncomplicated urinary tract infections in women and adolescents.

October 16th 2024

FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List

Your daily dose of the clinical news you may have missed.

Ashley Gallagher;Grace Halsey

October 15th 2024

FDA Approves Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections

Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.

Related Content

Patient Care Editorial Staff

October 25th 2024

FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions

Oral sulopenem is the first oral penem approved in the US for treating uUTIs in women with limited options.

FDA Updates Flublok Label with Safety Data for Pregnant Individuals

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

FDA Grants Priority Review to GSK NDA for First-In-Class Oral Antibiotic

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

October 16th 2024

FDA Approves Next-Gen Noninvasive CRC Screening Test: Daily Dose

The FDA today accepted GSK's NDA for gepotidacin for the treatment of uncomplicated urinary tract infections in women and adolescents.